Türkoğlu, Gamze, Berkem, Rukiye, Karakoç, Ayşe Esra · Mikrobiyoloji bulteni · 2018 · DOI
This study looked at a specific type of autoantibody (immune protein) called anti-DFS70 that can appear in blood tests. Researchers tested patient samples to see how often this antibody was present and whether it could help doctors diagnose autoimmune diseases. They found that this antibody sometimes appears in patients with chronic conditions like chronic fatigue syndrome, but it's not a reliable marker for typical autoimmune diseases.
This research is relevant because anti-DFS70 autoantibodies have been documented in chronic fatigue syndrome patients, and understanding their frequency and diagnostic value could help clarify whether they represent a distinct immune mechanism in ME/CFS or are simply a non-specific inflammatory marker. The study highlights the importance of accurate antibody detection methods when investigating immune abnormalities in conditions like ME/CFS that lack established biomarkers.
This study does not establish that anti-DFS70 antibodies cause chronic fatigue syndrome or that they are pathogenic rather than simply a biomarker of immune activation. The cross-sectional design cannot determine temporal relationships or whether these antibodies precede or follow disease onset. Additionally, the study does not characterize the clinical features or disease severity of CFS patients in their sample.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →